Clinical Trial Update: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

A Phase 1 trial investigating HDM201 in combination with MBG453 or venetoclax in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome

Drugs mentioned

• HDM201
• MBG453
• Venetoclax (venetoclax)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) | Phase 1 | Status: TERMINATED